As a physician in training, the continuing high burden of respiratory disease and the relative paucity of medicines soon became a driving force for my career as a doctor and scientist. Much of what I learned in the field, including critical care medicine, happened under the great mentorship and training I received at University College London. Over the years, I have been privileged to hold held several R&D and medical roles in both hospital, industry and academic settings including: VP and Head of the Fibrosis and Lung Injury R&D Unit at GSK, and most recently Chief Medical Officer at Galecto Biotech. I’ve also been able to publish over 50 original publications in journals such as The Lancet Respiratory Medicine, New England Journal of Medicine and Nature Communications. Then in 2019, it was the AstraZeneca offices in Cambridge that became my new home base.
As Global Head of Respiratory & Inflammation Late Stage Development, I work with a high performing team of biometrics, regulatory, operations, and clinical development experts to advance potential new medicines from phase IIb through submission and approval, and into life cycle management. Despite new launches in recent years, therapeutic advances are still needed to reduce the continuing morbidity and mortality from respiratory disease, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and chronic cough.
I have been here just a short while, but the energy, diligence and entrepreneurship at AZ is truly pushing the boundaries of science and improving treatment options for patients with Respiratory and Immunology-based diseases. We are committed to collaborating with experts, both within and outside AZ, to accelerate medicines development and transform patient care in inflammatory diseases of the airway, skin, joints, GI tract and beyond. With AstraZeneca’s strong Respiratory & Immunology pipeline, I have high expectations that we will continue to discover and develop new medicines over the coming years.
There is huge unmet need in inflammatory disease both in respiratory and beyond, and I am determined to push the boundaries to discover new ways to improve treatment options around the world.
First inhaled alpha-V beta-6 blocker tested in humans
Collagen biomarkers as predictors of outcome in IPF